Non-IgM Monoclonal Gammopathy of Undetermined Significance

Non-IgM Monoclonal Gammopathy of Undetermined Significance — Trials · CancerIndex

Clinical trials

Registered studies

3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06083922	A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)	recruiting	Phase 2	20	Memorial Sloan Kettering Cancer CenterOTHER	1	Jul 6, 2026	clinicaltrials
NCT06418477	Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD	recruiting	Phase 2	20	Peking University People's HospitalOTHER	1	Oct 1, 2024	clinicaltrials

Data updated 23 days agoSource updated Jul 6, 2026source: clinicaltrials